Vodafone UK, CK Hutchison Three's Merger Faces In-depth Probe From UK Antitrust Watchdog
Highlights of Malaysia's Bank Giants: FY23 Earnings Surge with Diversification and Innovation
The new trend of Mingshi Electric is hidden in humanoid robots | Jianzhi Research
Humanoid robot dexterous hand - hollow cup motor
After losing 700 million yuan, why did Longpan Technology, the “third largest in the world” for lithium iron phosphate cathodes, go to the Hong Kong Stock Exchange
Intended overseas
Zhaoyan's new drug to “hoard monkeys roll over” has come to a standstill
The fried monkey rolled over. Recently, the 2023 semi-annual report of Zhaoyan New Drug (603127.SH) predicted a sharp decline in net profit. According to the performance forecast, the net profit of Zhaoyan New Drug in the first half of 2023 is expected to be 73 million yuan to 110 million yuan, with a year-on-year decline range of 70.40% to 80.40%. Excluding the net profit of 188 million yuan in the first quarter of 2023, Zhaoyan New Pharmaceutical already lost money in the second quarter, only about -115 million yuan to -078 million yuan. However, at the same time, there was no sharp decline in revenue from Zhaoyan New Pharmaceuticals. In the first half of 2023
Nvidia is leaving AI pharmaceuticals, are CXO companies expected to take off?
Performance implementation pending examination